Scope of the Study
The diagnosis and treatment of parasitic diseases have changed significantly due to the increased awareness and technological advances that now allow faster and more accurate diagnosis of parasitic diseases. These advances are crucial for the further diagnosis of these infections, as the quantity and quality of laboratory technicians who are familiar with the classic techniques for examining stool and blood smears for parasites have steadily declined. The majority of laboratories are increasingly relying on non-classical parasitological techniques to accurately diagnose these infections. Prophylactic treatment is designed to prevent the occurrence and spread of parasitic diseases. Preventive chemotherapy is used to control the transmission of helminth infections within a community. Vendors in the market are also developing vaccines to prevent and control chronic diseases, including malaria and other diseases. In addition, researchers are studying physically attenuated parasites in a vaccine to control and prevent diseases such as leishmaniasis donovani and leishmaniasis braziliensi. Therefore, the increasing adoption of prophylactic vaccines for the prevention and control of parasitic diseases will accelerate the growth of the parasitic disease therapeutics market.
The market study is being classified by Type (Antiprotozoal Therapeutics, Anthelminthic Therapeutics and Scabicides and Pediculicides Therapeutics), by Application (Hospitals, Clinics and Homecare settings) and major geographies with country level break-up.
Bayer AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), GlaxoSmithKline Plc (United Kingdom), Pfizer Inc. (United States) and Sanaria Inc. (United States) are some of the key players profiled in the study.
The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies.
AdvanceMarketAnalytics has segmented the market of Global Parasitic Diseases Therapeutic market by Type, Application and Region.
On the basis of geography, the market of Parasitic Diseases Therapeutic has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- The Increasing Prevalence of the Parasitic Diseases
- Increasing Adoption of Prophylactic Treatment
- The Growing Acceptance of the Vaccines for the Prevention and Control of Parasite Diseases
- Increasing Expenditure to Boost the Penetration Rate of Treatments of the Parasitic Diseases
- Increased Drug Resistance
- Side-Effects of the Prescribed Drugs
- The Rising Initiatives and Programs to Eliminate Parasitic Diseases
- Increasing Clinical Trial Studies for the Development of New Drugs
- Lack of Effective Therapies
Key Target AudienceProviders of Parasitic Diseases Therapeutic, End-Users, Potential Investors, Market Research Firms, Regulatory Firms and Others
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase